Skip to main content
Clinical Trials/NCT05683925
NCT05683925
Completed
Not Applicable

Effect of Transcutaneous Auricular Vagus Nerve Stimulation at 25Hz and 100Hz on Levodopa Responsive and Non-responsive Gait Characteristics in Parkinson's Disease- a Motion Sensor Study

University Medical Centre Ljubljana1 site in 1 country30 target enrollmentSeptember 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
University Medical Centre Ljubljana
Enrollment
30
Locations
1
Primary Endpoint
Anticipatory Postural Adjustment (APA) duration
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

In this randomised placebo-controlled trial, the investigators will include 30 PD (Parkinson's disease) patients with HY (Hoehn Yahr stage) >2 and L-dopa unresponsive gait characteristics. Each participant will receive taVNS at 25Hz, taVNS at 100Hz and sham VNS (sVNS). During each stimulation, different gait characteristics will be measured with wearable insertion motion sensors.

Detailed Description

Participants and study overview: In this randomised placebo-controlled trial, the investigators will include 30 PD patients with HY\>2 and L-dopa unresponsive gait characteristics. Each participant will complete 1 visit, during which the instrumented stand and walk test will be repeated 16 times. The baseline measurement will be followed by three different stimulation conditions sham VNS (sVNS), taVNS at 25Hz (taVNS25) and taVNS a 100Hz (taVNS100). sVNS, taVNS25 and taVNS100 in a randomized order. To enhance gait disturbances, the participants will perform iSAW during each condition twice in silence and twice while simultaneously performing calculations around. Instrumented stand and walk test (iSAW): To perform iSAW, participants will first stand still for 30s, after which they will start walking in a straight line for 7m, turn and walk back to the start. The participants will be equipped with 6 inertion Opal ® motion sensors (on both feet, both wrists, on the lumbar back and on their sternum). For the laud counting iSAW condition (iSAW-C), the participants will perform iSAW as described above while also counting backwards by 3 from numbers above 100. TaVNS: Noninvasive electrostimulation will be applied to the left ear. taVNS will be applied to the cyma conchae and sVNS will be applied to the earlobe. Both taVNS and sVNS were applied through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold (figure 1). taVNS25 and sVNS will be applied at 25Hz and taVNS100 will be applied at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment. For each condition, the electrode will be placed in the ear by a third person and the ear will be covered by cotton pads and an EEG cap to hide the electrode position from the experimenter. The order of stimulation will not be revealed until the automated data and statistical analysis.

Registry
clinicaltrials.gov
Start Date
September 1, 2022
End Date
February 15, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Maja Kojović

assoc. prof.

University Medical Centre Ljubljana

Eligibility Criteria

Inclusion Criteria

  • HYstage \>2
  • L-dopa unresponsive gait characteristics present, preferably with history of freezings

Exclusion Criteria

  • unable to walk for 50m
  • unable to follow simple commands due to hearing loss/cognitive impairment

Outcomes

Primary Outcomes

Anticipatory Postural Adjustment (APA) duration

Time Frame: This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.

The average duration of anticipatory postural adjustments in seconds as produced by the Mobility Lab software.

APA First step Duration

Time Frame: This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.

The average duration of the first detected step in seconds as produced by the Mobility Lab software.

Arm Range of Motion

Time Frame: This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.

The average wrist range of motion in degrees as produced by the Mobility Lab software.

Gait Speed

Time Frame: This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.

The average speed of gait in m/s as produced by the Mobility Lab software.

APA First Step range of motion

Time Frame: This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.

The average range of motion of the first detected step as produced by the Mobility Lab software.

Arm Swing Velocity

Time Frame: This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.

The average velocity of upper extremities in degrees per second as produced by the Mobility Lab software.

Stride Length

Time Frame: This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.

The average stride length in m as produced by the Mobility Lab software.

Arm Range of Motion Asymmetry

Time Frame: This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.

The average difference between left and right arm range of motion in degrees as produced by the Mobility Lab software.

Study Sites (1)

Loading locations...

Similar Trials